Header Logo

Connection

CLIONA ROONEY to Epstein-Barr Virus Infections

Back to Details
This is a "connection" page, showing publications CLIONA ROONEY has written about Epstein-Barr Virus Infections.
CLIONA ROONEY
Connection Strength
6.689
Epstein-Barr Virus Infections
  1. Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein-Barr Virus-Specific T-Cells. Int J Mol Sci. 2023 Oct 31; 24(21).
    View in: PubMed
    Score: 0.711
  2. A Costimulatory CAR Improves TCR-based Cancer Immunotherapy. Cancer Immunol Res. 2022 04 01; 10(4):512-524.
    View in: PubMed
    Score: 0.637
  3. Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas. J Clin Oncol. 2021 02 10; 39(5):514-524.
    View in: PubMed
    Score: 0.585
  4. Adoptive T-Cell Immunotherapy. Curr Top Microbiol Immunol. 2015; 391:427-54.
    View in: PubMed
    Score: 0.385
  5. Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Cytotherapy. 2011 May; 13(5):518-22.
    View in: PubMed
    Score: 0.295
  6. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35.
    View in: PubMed
    Score: 0.269
  7. Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas. Blood Adv. 2025 Apr 08; 9(7):1658-1669.
    View in: PubMed
    Score: 0.196
  8. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma. 2005 Jan; 46(1):1-10.
    View in: PubMed
    Score: 0.193
  9. Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma. Blood Adv. 2024 07 09; 8(13):3360-3371.
    View in: PubMed
    Score: 0.186
  10. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004 Jul-Aug; 27(4):317-27.
    View in: PubMed
    Score: 0.186
  11. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15. Cytotherapy. 2003; 5(3):231-40.
    View in: PubMed
    Score: 0.168
  12. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003 Mar 01; 101(5):1905-12.
    View in: PubMed
    Score: 0.166
  13. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002 Dec 01; 100(12):4059-66.
    View in: PubMed
    Score: 0.163
  14. Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Adv. 2022 02 08; 6(3):891-901.
    View in: PubMed
    Score: 0.158
  15. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res. 2002; 159:123-33.
    View in: PubMed
    Score: 0.157
  16. Immune therapy for EBV infections after hemopoietic stem-cell transplant. Cytotherapy. 2002; 4(5):433-4.
    View in: PubMed
    Score: 0.157
  17. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Ann Hematol. 2021 Oct; 100(10):2529-2539.
    View in: PubMed
    Score: 0.152
  18. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001 Feb 15; 97(4):835-43.
    View in: PubMed
    Score: 0.147
  19. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.
    View in: PubMed
    Score: 0.125
  20. EBV specific CTL: a model for immune therapy. Vox Sang. 1998; 74 Suppl 2:497-8.
    View in: PubMed
    Score: 0.119
  21. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas. Methods Mol Biol. 2017; 1532:255-265.
    View in: PubMed
    Score: 0.111
  22. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.
    View in: PubMed
    Score: 0.086
  23. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol. 2012 Sep; 9(9):510-9.
    View in: PubMed
    Score: 0.081
  24. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest. 2012 Apr; 122(4):1487-502.
    View in: PubMed
    Score: 0.079
  25. Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. Pediatr Blood Cancer. 2012 Oct; 59(4):758-61.
    View in: PubMed
    Score: 0.077
  26. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther. 2011 Dec; 19(12):2133-43.
    View in: PubMed
    Score: 0.076
  27. Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant. 2011 Jun; 16(3):274-80.
    View in: PubMed
    Score: 0.075
  28. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011 Jun 02; 117(22):5835-49.
    View in: PubMed
    Score: 0.074
  29. Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation. Immunotherapy. 2010 Sep; 2(5):663-71.
    View in: PubMed
    Score: 0.071
  30. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009 Nov 05; 114(19):4283-92.
    View in: PubMed
    Score: 0.066
  31. Improving T cell therapy for cancer. Annu Rev Immunol. 2007; 25:243-65.
    View in: PubMed
    Score: 0.055
  32. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant. 2006 Nov-Dec; 20(6):689-94.
    View in: PubMed
    Score: 0.055
  33. Adoptive immunotherapy for Hodgkin's lymphoma. Int J Hematol. 2006 Jun; 83(5):385-90.
    View in: PubMed
    Score: 0.053
  34. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant. 2006 May-Jun; 20(3):389-93.
    View in: PubMed
    Score: 0.053
  35. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005 Sep; 5(9):2222-8.
    View in: PubMed
    Score: 0.050
  36. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant. 2005 Mar; 5(3):566-72.
    View in: PubMed
    Score: 0.049
  37. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation. 2004 Sep 15; 78(5):755-7.
    View in: PubMed
    Score: 0.047
  38. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004 May 15; 103(10):3979-81.
    View in: PubMed
    Score: 0.045
  39. Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist. 2003; 8(1):83-98.
    View in: PubMed
    Score: 0.042
  40. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol. 2003; 110(2-3):139-48.
    View in: PubMed
    Score: 0.042
  41. Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease. Acta Haematol. 2003; 110(2-3):149-53.
    View in: PubMed
    Score: 0.042
  42. Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol. 2002 Sep; 118(3):728-40.
    View in: PubMed
    Score: 0.041
  43. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002 Jan 15; 168(2):909-18.
    View in: PubMed
    Score: 0.039
  44. Gene and cell transfer for specific immunotherapy. Vox Sang. 1998; 74 Suppl 2:87-90.
    View in: PubMed
    Score: 0.030
  45. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21.
    View in: PubMed
    Score: 0.022
  46. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011 Dec; 19(12):2258-68.
    View in: PubMed
    Score: 0.019
  47. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009 Mar 12; 113(11):2442-50.
    View in: PubMed
    Score: 0.016
  48. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007 Oct 15; 110(8):2838-45.
    View in: PubMed
    Score: 0.014
  49. Slc11a1 (formerly Nramp1) polymorphisms and susceptibility to post-transplant lymphoproliferative disease following pediatric liver transplantation. Transpl Infect Dis. 2006 Jun; 8(2):108-12.
    View in: PubMed
    Score: 0.013
  50. Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002; 8(1):1-8.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.